A research team led by Prof. Liu Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Science has ...

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

The FDA had earlier accepted CYTK’s new drug application (NDA) for lead pipeline candidate aficamten and assigned a standard review to the candidate with a target action date of Sept. 26, 2025.

Cytokinetics, Incorporated announced that the FDA has extended the action date for aficamten, a treatment for obstructive hypertrophic cardiomyopathy (oHCM), to December 26, 2025. The extension is ...

PITTSBURGH-- (BUSINESS WIRE)-- #CRS --CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the ...

Research on cytokine action in the brain began with the exploration of fever physiology and subsequently broadened to include all aspects of immune physiology [47].

Objectives To evaluate the potential of clinical factors, ultrasound findings, serum autoantibodies, and serum cytokine and chemokine profiles as predictors of clinical outcomes in rheumatoid ...

Potential Positives Positive guidance on the PDUFA target action date for aficamten, set for September 26, 2025, indicating potential near-term revenue opportunities.